Neurology Today
Neurology Today serves as the official news platform for the American Academy of Neurology (AAN), providing timely updates on important news, developments, and trends in the field of neurology to an audience of over 20,000 professionals. This publication offers reliable, current, and insightful reporting and commentary tailored for the fast-paced lives of today's neurologists. Released bi-monthly, Neurology Today also grants readers exclusive access to essential information from the AAN, its official journal Neurology, and various other neurology-related publications.
Outlet metrics
Global
N/A
Country
N/A
Category
N/A
Articles
-
2 weeks ago |
journals.lww.com | Dawn Fallik
Tolebrutinib, a brain-penetrant Bruton tyrosine (BTK) inhibitor, significantly slowed disability progression in multiple sclerosis, according to research from two different phase 3 trials presented at the AAN Annual Meeting in San Diego.
-
3 weeks ago |
journals.lww.com | Gina Shaw
Use of over-the-counter (OTC) analgesics—including both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)—after a traumatic brain injury (TBI) was significantly associated with improved concussion symptoms and recovery, according to new data presented at the AAN Annual Meeting in San Diego. The prospective cohort study of National Collegiate Athletic Association (NCAA) and military cadets also found that the OTC drugs led to a quicker return to play.
-
3 weeks ago |
journals.lww.com | Gina Shaw
Modern hormonal contraceptives, which contain substantially lower doses of estrogen compared with earlier-generation high-dose combined oral contraceptives, are not associated with an increased risk of stroke and other vascular events in women with migraine, both with and without aura, according to findings presented at the AAN Annual Meeting in San Diego. The large study used data from a nationwide de-identified electronic health record database.
-
3 weeks ago |
journals.lww.com | Gina Shaw
Inebilizumab (Uplizna), a monoclonal antibody targeting CD19+ B-cells, significantly improves disease severity in patients with generalized myasthenia gravis (MG), according to new findings from the MINT phase 3 clinical trial presented at the AAN Annual Meeting in San Diego.
-
3 weeks ago |
journals.lww.com | Gina Shaw
Fremanezumab (Ajovy)—a calcitonin gene-related peptide agonist (CGRP)— is safe and effective for prevention of episodic migraine in children and adolescents as young as 6 years old, according to findings presented at the AAN 2025 Annual Meeting in San Diego, The multicenter, double-blind, parallel-group, phase 3 study—led by headache medicine specialist and child neurologist Andrew Hersey, MD, PhD, FAAN, endowed chair and director of the division of neurology at Cincinnati Children's...
Neurology Today journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →